Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)

NCT05429268 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

82

Enrollment

INDUSTRY

Sponsor class

Conditions

Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma

Interventions

DRUG: Tafasitamab
DRUG: Lenalidomide

Sponsor

Incyte Corporation